Log-in
Sign-up
Webcast
Clinical Trials
Library
Webcast
Clinical Trials
Library
Home
>
Clinical Trials
Molecules
전체
Edoxaban
Olmesartan
Prasugrel
Pravastatin
Mirogabalin
Ramosetron
Trastuzumab deruxtecan
Status
Select
Check All
Search
Recruiting
Completed
Not yet recruiting
Enrolling by invitation
Active, not recruiting
Suspended
Terminated
Withdrawn
Unknown status
Email
Saved trials
NOT_YET_RECRUITING
NCT07126561
Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers
43
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (PHASE2)
HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2
RECRUITING
NCT06899126
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
686
Enrollment(s)
100
Study location(s)
INTERVENTIONAL (PHASE3)
Non-small Cell Lung Cancer
RECRUITING
NCT07195149
Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)
1,703
Enrollment(s)
18
Study location(s)
INTERVENTIONAL (PHASE3)
Chronic Coronary Syndrome
Stable Coronary Artery Disease CAD
RECRUITING
NCT06324396
IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease
15
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (PHASE1)
Fontan Circulation
ACTIVE_NOT_RECRUITING
NCT05480384
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
1
Enrollment(s)
2
Study location(s)
INTERVENTIONAL (PHASE2)
Esophageal Adenocarcinoma
Esophageal Cancer
HER-2 Protein Overexpression
Gastroesophageal-junction Cancer
TERMINATED
NCT03820947
VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial
506
Enrollment(s)
32
Study location(s)
INTERVENTIONAL (NA)
Venous Reflux
ACTIVE_NOT_RECRUITING
NCT05048797
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
454
Enrollment(s)
130
Study location(s)
INTERVENTIONAL (PHASE3)
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
TERMINATED
NCT03944512
Pravastatin to Prevent Preeclampsia
102
Enrollment(s)
12
Study location(s)
INTERVENTIONAL (PHASE3)
Preeclampsia
Obstetric Labor Complications
Hypertension in Pregnancy
11
12
13
14
15